TFG, trafficking from ER to golgi regulator, plays a role in regulation of intracellular trafficking and plays a role in the COPII-coated vesicle transport system. TFG fusions, with multiple gene partners, have been identified in several tumor types, including TFG-MET in thyroid carcinoma, TFG-RET in papillary thyroid cancer, TFG-FGFR1 in AML, and TFG-NR4A3 in extraskeletal myxoid chondrosarcoma.

MET, MET proto-oncogene, receptor tyrosine kinase, is a receptor tyrosine kinase, which activates MAPK, PI3K/AKT, SRC, and STAT pathways to promote cell proliferation, invasion, and angiogenesis. MET mutations, exon 14 skipping mutations, and fusions have been identified in a variety of human cancers, including lung cancer, and MET amplification and/or overexpression has been reported in many solid tumors, including biliary tract cancer, breast cancer, NSCLC, gastric cancer, intrahepatic cholangiocarcinoma, and gallbladder carcinoma.

1. Anti-proliferation assay